Cargando…
Comparison of SARS-CoV-2 Antibodies and Six Immunoassays in Pediatric and Adult Patients 12 Weeks After COVID-19
Introduction Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific humoral immune persistence has been proposed to be affected by patients’ characteristics. Moreover, available conflicting assay results are needed to be settled through comparative research with defined clinical speci...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924986/ https://www.ncbi.nlm.nih.gov/pubmed/35308741 http://dx.doi.org/10.7759/cureus.22195 |
_version_ | 1784669972079837184 |
---|---|
author | Saglik, Imran Turkkan, Alparslan Turan, Cansu Kara, Ates Akalin, Halis Ener, Beyza Sahin, Ahmet Yesil, Edanur Celebi, Solmaz Kazak, Esra Heper, Yasemin Yilmaz, Emel Korkmaz, Muhammet Furkan Ture, Esra Hacimustafaoglu, Mustafa |
author_facet | Saglik, Imran Turkkan, Alparslan Turan, Cansu Kara, Ates Akalin, Halis Ener, Beyza Sahin, Ahmet Yesil, Edanur Celebi, Solmaz Kazak, Esra Heper, Yasemin Yilmaz, Emel Korkmaz, Muhammet Furkan Ture, Esra Hacimustafaoglu, Mustafa |
author_sort | Saglik, Imran |
collection | PubMed |
description | Introduction Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific humoral immune persistence has been proposed to be affected by patients’ characteristics. Moreover, available conflicting assay results are needed to be settled through comparative research with defined clinical specimens. Methods This prospective study investigated SARS-CoV-2-specific antibodies among 43 adults and 34 children at a mean of 12 weeks after the onset of COVID-19 symptoms using six serological assays and compared their performance. We used two Euroimmun (Euroimmun, Luebeck, Germany), two automated Roche Elecsys (Basel, Switzerland), and two rapid immuno-chromatographic Ecotest (Matrix Diagnostics, Assure Tech. (Hangzhou) Co., L, China) assays to investigate SARS-CoV-2 antibodies. Results The findings showed that the Roche Elecsys anti-S total test yielded the best positivity/sensitivity (children 94.1% and adults 93.0%; p = 0.877) while five immunoglobulin IgG targeting assays had similar positivity/sensitivity between children (88.2% to 94.1%) and adults (88.4% to 93.0%) (p > 0.05). Although IgM positivity was relatively low (p < 0.001), it was found in the majority of our pediatric and adult patients (67.6% and 86.0%, respectively; p = 0.098). SARS-CoV-2 S IgG titers were found to be higher among males in pediatric and adult groups compared to females (p = 0.027 and p = 0.041, respectively). Furthermore, we observed significantly higher antibody titers among pneumonia patients (p = 0.001). Conclusion Overall, we concluded SARS-CoV-2 antibody persistence over an average of 12 weeks after the onset of COVID-19 symptoms. While automated Roche Elecsys total antibody assays yielded the best sensitivity (> 90%) and five assays targeting IgG had acceptable performance. Patients with pneumonia and males have higher antibody titers. The effect of antibody persistence on re-infections should be monitored in longitudinal studies. |
format | Online Article Text |
id | pubmed-8924986 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-89249862022-03-18 Comparison of SARS-CoV-2 Antibodies and Six Immunoassays in Pediatric and Adult Patients 12 Weeks After COVID-19 Saglik, Imran Turkkan, Alparslan Turan, Cansu Kara, Ates Akalin, Halis Ener, Beyza Sahin, Ahmet Yesil, Edanur Celebi, Solmaz Kazak, Esra Heper, Yasemin Yilmaz, Emel Korkmaz, Muhammet Furkan Ture, Esra Hacimustafaoglu, Mustafa Cureus Infectious Disease Introduction Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific humoral immune persistence has been proposed to be affected by patients’ characteristics. Moreover, available conflicting assay results are needed to be settled through comparative research with defined clinical specimens. Methods This prospective study investigated SARS-CoV-2-specific antibodies among 43 adults and 34 children at a mean of 12 weeks after the onset of COVID-19 symptoms using six serological assays and compared their performance. We used two Euroimmun (Euroimmun, Luebeck, Germany), two automated Roche Elecsys (Basel, Switzerland), and two rapid immuno-chromatographic Ecotest (Matrix Diagnostics, Assure Tech. (Hangzhou) Co., L, China) assays to investigate SARS-CoV-2 antibodies. Results The findings showed that the Roche Elecsys anti-S total test yielded the best positivity/sensitivity (children 94.1% and adults 93.0%; p = 0.877) while five immunoglobulin IgG targeting assays had similar positivity/sensitivity between children (88.2% to 94.1%) and adults (88.4% to 93.0%) (p > 0.05). Although IgM positivity was relatively low (p < 0.001), it was found in the majority of our pediatric and adult patients (67.6% and 86.0%, respectively; p = 0.098). SARS-CoV-2 S IgG titers were found to be higher among males in pediatric and adult groups compared to females (p = 0.027 and p = 0.041, respectively). Furthermore, we observed significantly higher antibody titers among pneumonia patients (p = 0.001). Conclusion Overall, we concluded SARS-CoV-2 antibody persistence over an average of 12 weeks after the onset of COVID-19 symptoms. While automated Roche Elecsys total antibody assays yielded the best sensitivity (> 90%) and five assays targeting IgG had acceptable performance. Patients with pneumonia and males have higher antibody titers. The effect of antibody persistence on re-infections should be monitored in longitudinal studies. Cureus 2022-02-14 /pmc/articles/PMC8924986/ /pubmed/35308741 http://dx.doi.org/10.7759/cureus.22195 Text en Copyright © 2022, Saglik et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Infectious Disease Saglik, Imran Turkkan, Alparslan Turan, Cansu Kara, Ates Akalin, Halis Ener, Beyza Sahin, Ahmet Yesil, Edanur Celebi, Solmaz Kazak, Esra Heper, Yasemin Yilmaz, Emel Korkmaz, Muhammet Furkan Ture, Esra Hacimustafaoglu, Mustafa Comparison of SARS-CoV-2 Antibodies and Six Immunoassays in Pediatric and Adult Patients 12 Weeks After COVID-19 |
title | Comparison of SARS-CoV-2 Antibodies and Six Immunoassays in Pediatric and Adult Patients 12 Weeks After COVID-19 |
title_full | Comparison of SARS-CoV-2 Antibodies and Six Immunoassays in Pediatric and Adult Patients 12 Weeks After COVID-19 |
title_fullStr | Comparison of SARS-CoV-2 Antibodies and Six Immunoassays in Pediatric and Adult Patients 12 Weeks After COVID-19 |
title_full_unstemmed | Comparison of SARS-CoV-2 Antibodies and Six Immunoassays in Pediatric and Adult Patients 12 Weeks After COVID-19 |
title_short | Comparison of SARS-CoV-2 Antibodies and Six Immunoassays in Pediatric and Adult Patients 12 Weeks After COVID-19 |
title_sort | comparison of sars-cov-2 antibodies and six immunoassays in pediatric and adult patients 12 weeks after covid-19 |
topic | Infectious Disease |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924986/ https://www.ncbi.nlm.nih.gov/pubmed/35308741 http://dx.doi.org/10.7759/cureus.22195 |
work_keys_str_mv | AT saglikimran comparisonofsarscov2antibodiesandsiximmunoassaysinpediatricandadultpatients12weeksaftercovid19 AT turkkanalparslan comparisonofsarscov2antibodiesandsiximmunoassaysinpediatricandadultpatients12weeksaftercovid19 AT turancansu comparisonofsarscov2antibodiesandsiximmunoassaysinpediatricandadultpatients12weeksaftercovid19 AT karaates comparisonofsarscov2antibodiesandsiximmunoassaysinpediatricandadultpatients12weeksaftercovid19 AT akalinhalis comparisonofsarscov2antibodiesandsiximmunoassaysinpediatricandadultpatients12weeksaftercovid19 AT enerbeyza comparisonofsarscov2antibodiesandsiximmunoassaysinpediatricandadultpatients12weeksaftercovid19 AT sahinahmet comparisonofsarscov2antibodiesandsiximmunoassaysinpediatricandadultpatients12weeksaftercovid19 AT yesiledanur comparisonofsarscov2antibodiesandsiximmunoassaysinpediatricandadultpatients12weeksaftercovid19 AT celebisolmaz comparisonofsarscov2antibodiesandsiximmunoassaysinpediatricandadultpatients12weeksaftercovid19 AT kazakesra comparisonofsarscov2antibodiesandsiximmunoassaysinpediatricandadultpatients12weeksaftercovid19 AT heperyasemin comparisonofsarscov2antibodiesandsiximmunoassaysinpediatricandadultpatients12weeksaftercovid19 AT yilmazemel comparisonofsarscov2antibodiesandsiximmunoassaysinpediatricandadultpatients12weeksaftercovid19 AT korkmazmuhammetfurkan comparisonofsarscov2antibodiesandsiximmunoassaysinpediatricandadultpatients12weeksaftercovid19 AT tureesra comparisonofsarscov2antibodiesandsiximmunoassaysinpediatricandadultpatients12weeksaftercovid19 AT hacimustafaoglumustafa comparisonofsarscov2antibodiesandsiximmunoassaysinpediatricandadultpatients12weeksaftercovid19 |